Characterization of Heparin-binding Site of Tissue Transglutaminase
Open Access
- 1 April 2012
- journal article
- Published by Elsevier BV
- Vol. 287 (16), 13063-13083
- https://doi.org/10.1074/jbc.m111.294819
Abstract
No abstract availableThis publication has 44 references indexed in Scilit:
- A Crucial Sequence for Transglutaminase Type 2 Extracellular Trafficking in Renal Tubular Epithelial Cells Lies in Its N-terminal β-Sandwich DomainPublished by Elsevier BV ,2011
- SST0001, a Chemically Modified Heparin, Inhibits Myeloma Growth and Angiogenesis via Disruption of the Heparanase/Syndecan-1 AxisClinical Cancer Research, 2011
- RGD-independent Cell Adhesion via a Tissue Transglutaminase-Fibronectin Matrix Promotes Fibronectin Fibril Deposition and Requires Syndecan-4/2 and α5β1 Integrin Co-signalingOnline Journal of Public Health Informatics, 2010
- Redox Regulation of Transglutaminase 2 ActivityPublished by Elsevier BV ,2010
- Increased TG2 Expression Can Result in Induction of Transforming Growth Factor β1, Causing Increased Synthesis and Deposition of Matrix Proteins, Which Can Be Regulated by Nitric OxideOnline Journal of Public Health Informatics, 2009
- Heparan Sulfate Proteoglycans Are Receptors for the Cell-surface Trafficking and Biological Activity of Transglutaminase-2Published by Elsevier BV ,2009
- Membrane Type 1 Matrix Metalloproteinase–Mediated Stromal Syndecan-1 Shedding Stimulates Breast Carcinoma Cell ProliferationCancer Research, 2008
- Fibronectin-Tissue Transglutaminase Matrix Rescues RGD-impaired Cell Adhesion through Syndecan-4 and β1 Integrin Co-signalingOnline Journal of Public Health Informatics, 2008
- Transglutaminase 2 Undergoes a Large Conformational Change upon ActivationPLoS Biology, 2007
- Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myelomaBlood, 2007